Boryung has teamed up with Skylabs to conduct space testing of a wearable blood pressure monitor.
On November 3, Boryung announced that it signed a memorandum of understanding (MOU) with medical device company Skylabs to develop astronaut biosignal monitoring solutions and establish a space medical data platform. The two companies plan to apply Skylabs' wearable biosignal monitoring products, including the blood pressure monitor, to Boryung's upcoming space environment simulation laboratory and infrastructure to validate the technology's effectiveness.
Boryung will provide the necessary testing environment for the research project and pursue follow-up joint research through its space medical research support program, 'Humans In Space (HIS).' The company is also considering linking HIS research data with Skylabs' artificial intelligence (AI) medical data production platform.
Last October, Skylabs conducted blood pressure measurement experiments using the wearable monitor in a near-weightless environment created in collaboration with a research team from the University of Cambridge and the International Institute for Advanced Space Studies (IIAS). This agreement aims to expand the product validation scope to actual space environments.
Boryung has been laying the groundwork for its space business by investing in Axiom Space and Intuitive Machines. Notably, it established a joint venture, 'Braxis Space,' with Axiom Space to secure domestic business rights for space research infrastructure.
Boryung described this agreement as a confirmation of the research needs of domestic medical device companies at the stage of building space infrastructure. Continuous measurement and analysis of biosignals, such as blood pressure, in space are expected to contribute not only to astronaut health management but also to cardiovascular disease research on Earth.
Lim Dong-joo, head of Boryung's Strategic Business Division, stated, "We will leverage the infrastructure and network we have secured to help domestic companies expand into international markets."
On November 3, Boryung announced that it signed a memorandum of understanding (MOU) with medical device company Skylabs to develop astronaut biosignal monitoring solutions and establish a space medical data platform. The two companies plan to apply Skylabs' wearable biosignal monitoring products, including the blood pressure monitor, to Boryung's upcoming space environment simulation laboratory and infrastructure to validate the technology's effectiveness.
Boryung will provide the necessary testing environment for the research project and pursue follow-up joint research through its space medical research support program, 'Humans In Space (HIS).' The company is also considering linking HIS research data with Skylabs' artificial intelligence (AI) medical data production platform.
Last October, Skylabs conducted blood pressure measurement experiments using the wearable monitor in a near-weightless environment created in collaboration with a research team from the University of Cambridge and the International Institute for Advanced Space Studies (IIAS). This agreement aims to expand the product validation scope to actual space environments.
Boryung has been laying the groundwork for its space business by investing in Axiom Space and Intuitive Machines. Notably, it established a joint venture, 'Braxis Space,' with Axiom Space to secure domestic business rights for space research infrastructure.
Boryung described this agreement as a confirmation of the research needs of domestic medical device companies at the stage of building space infrastructure. Continuous measurement and analysis of biosignals, such as blood pressure, in space are expected to contribute not only to astronaut health management but also to cardiovascular disease research on Earth.
Lim Dong-joo, head of Boryung's Strategic Business Division, stated, "We will leverage the infrastructure and network we have secured to help domestic companies expand into international markets."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.